The purpose of this RFP is to allow Research projects to implement and observe the therapy management approach for patients suffering from HER2+ Metastatic Breast Cancer (mBC).
The Pfizer Grant calls organizations to submit applications for initiatives implementing innovative and easy accessible approaches to improve therapy management with the 3-drug regimen of tucatinib, trastuzumab and capecitabine. The project should also aim to understand the patients’ quality of life, their adherence to treatment, facilitate follow-up or symptom management in everyday clinical practice.
Apart from the above the project should also aim at providing patient care through research framework or “Health Services Research” type approach in order assess the impact of the interventions. The funding is for individual projects up to $250,000 and the duration of project is 18-month suggested project length (may be shorter or longer).
Therapy management programs may include the following interventions: utilization of digital tools making patients monitoring easy through Apps, Education tools on safety profile and adverse events management such as infographics, training sessions, Patient Advocacy Group engagement, Multidisciplinary management: Primary Care Provider or General Practitioner engagement, oncology nurse consultations, call center, etc.
Last date to apply: January 30, 2025. Please find more information here: https://cdn.pfizer.com/pfizercom/2024-11/tucatinib_therapy_management_research_ISR_RFP2024.pdf?VersionId=6eDQRTtO5SY0F.aPoYMoU431vuOy6hHd
